Adverse events and real-world outcomes of intravenous immunoglobulin in dermatological diseases: a 20-year cohort study
Clinical and Experimental Dermatology · 17.09.2026
DOI: 10.1093/ced/llag410 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 17.09.2026. Verfasst von Kenan Aydogan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bursa Uludağ University, Dermatology and Venereology, Bursa Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Intravenous immunoglobulin (IVIG) is widely used in dermatology for severe and refractory immune-mediated diseases; however, comprehensive real-world data regarding its effectiveness and safety across diverse dermatological diseases remain limited.
Objectives
To evaluate the clinical outcomes and adverse events (AEs) associated with IVIG therapy in patients with dermatological diseases treated in routine clinical practice.
Methods
A retrospective cohort study was conducted that included 285 patients who received IVIG at a tertiary dermatology centre between January 2001 and November 2021. Demographic characteristics, diagnoses, comorbidities, treatment responses, and immediate and delayed AEs were analysed.
Results
The majority of patients had autoimmune bullous diseases (n = 176/285; 61.8%). Favourable clinical outcomes were observed across disease groups, particularly in autoimmune bullous diseases and the Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) spectrum. AEs occurred in 44 patients (15.4%) and included both immediate and delayed reactions. Hypertension and influenza-like symptoms were the most common immediate reactions, while renal impairment and thromboembolic events were the most frequent delayed complications. AEs were not associated with the underlying dermatological disease but were significantly more common in patients with comorbidities (77.3% vs. 8.3%, P < 0.001).
Conclusions
IVIG was associated with favourable clinical outcomes and was generally well tolerated in this retrospective cohort; however, careful assessment of patient comorbidities and individualized infusion strategies may help minimize treatment-related AEs.
Autor:innen und Institutionen
- Bursa Uludağ University, Dermatology and Venereology, Bursa Türkiye.
- Ümraniye Training and Research Hospital, Dermatology and Venereology, İstanbul, Türkiye.
ORCID-Profile: Cansu Irmak Ünlü
Zitieren
APA
Aydogan, K., Ünlü, C. I., Öztürk, F., Saricaoglu, H., Baskan, E. B., & Yazici, S. (2026). Adverse events and real-world outcomes of intravenous immunoglobulin in dermatological diseases: a 20-year cohort study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag410
Vancouver
Aydogan K, Ünlü CI, Öztürk F, Saricaoglu H, Baskan EB, Yazici S. Adverse events and real-world outcomes of intravenous immunoglobulin in dermatological diseases: a 20-year cohort study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag410
BibTeX
@article{Aydogan2026,
author = {Aydogan, Kenan and Ünlü, Cansu Irmak and Öztürk, Ferdi and Saricaoglu, Hayriye and Baskan, Emel Bulbul and Yazici, Serkan},
title = {Adverse events and real-world outcomes of intravenous immunoglobulin in dermatological diseases: a 20-year cohort study},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag410}
}
EUVIMED